PROKIDNEY CORP. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ProKidney completed enrollment of ~320 patients for the Phase 3 PROACT 1 accelerated approval efficacy analysis, with topline eGFR slope results expected in Q2 2027. Full trial enrollment (~470 patients) on track for H2 2026, with confirmatory results anticipated H2 2029. Company ended Q2 2026 with $181.6M cash (vs. $224.9M in Q1 2026), R&D expenses rose to $36.1M (Q2 2026 vs. $25.9M in Q2 2025), and net loss was $46.4M for the quarter.
Why this rating
Phase 3 enrollment milestone in lead cell therapy program is material for a $58.9M biotech; Q2 2027 data catalyst is near-term catalyst. Cash adequate through mid-2027 but burn rate elevated. Significant relative to company scale but execution risk remains.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.